Recombinant Capture Molecule Used for Viral Disease Diagnosis
By LabMedica International staff writers Posted on 17 Apr 2019 |
Image: The SPECTROstar Nano Absorbance plate reader with cuvette port (Photo courtesy of BMG Labtech).
Crimean-Congo hemorrhagic fever (CCHF) is an infectious disease endemic in a variety of countries in southeastern Europe, the Middle East, Asia, and Africa. The virus (CCHFV) transmission occurs via the bite of an infected tick and also by close contact with body fluids of infected persons or livestock.
The Zika Virus (ZIKV) is an arbovirus that belongs to the Flavivirus genus and infection follows the bite of an infected Aedes mosquito, and it presents with mild flulike disease symptoms; asymptomatic infection is frequent. A ZIKV infection occurring during the first trimester of pregnancy significantly increases the probability for the fetus to develop microcephaly, a severe and disabling malformation of the brain.
An international team of scientists working with the Bernhard Nocht Institute for Tropical Medicine (Hamburg, Germany) have demonstrate the potential of the bacterially expressed extracellular immunoglobulin-like domain of the human FcμR (HsFcμR-Igl) as a capture molecule for IgM-specific serological testing. As model systems, they chose two viral pathogens, the CCHFV and the ZIKV. In 2015, both were identified as high-risk emerging pathogens by the World Health Organization (WHO, Geneva, Switzerland) likely to cause major epidemics and thus needing urgent investigation and development attention.
His-tagged HsFcμR-Igl was expressed in Escherichia coli and purified by affinity chromatography, oxidative refolding, and size-exclusion chromatography. Specific binding of HsFcμR-Igl to IgM/antigen immune complexes (ICs) was confirmed, and two prototypic enzyme-linked immunosorbent assays (ELISAs) for the detection of anti-CCHFV and anti-ZIKV IgM antibodies were developed. Thereby, patient sera and virus-specific recombinant antigens directly labeled with horseradish peroxidase (HRP) were co-incubated on HsFcμR-Igl-coated ELISA plates. Bound ICs were quantified by measuring turnover of a chromogenic HRP substrate. For all ELISAs, the HRP reaction product was quantified by measuring absorbance (A) at 450 nm and 620 nm on a Spectrostar Nano ELISA reader.
Assay validation was performed using paired serum samples from 15 Kosovar patients with a polymerase chain reaction (PCR)-confirmed CCHFV infection and 28 Brazilian patients with a PCR-confirmed ZIKV infection, along with a panel of a priori CCHFV/ZIKV-IgM-negative serum samples. Both ELISAs were highly reproducible. Sensitivity and specificity were comparable with or even exceeded in-house gold standard testing and commercial kits. Furthermore, latex beads coated with HsFcμR-Igl aggregated upon co-incubation with an IgM-positive serum and HRP-labeled antigen but not with either component alone, revealing a potential for use of HsFcμR-Igl as a capture molecule in aggregation-based rapid tests.
The authors concluded that recombinant HsFcμR-Igl is a versatile capture molecule for IgM/antigen ICs of human and animal origin and can be applied for the development of both plate- and bead-based serological tests. The study was published in the February 2019 issue of the journal Clinical Chemistry.
Related Links:
Bernhard Nocht Institute for Tropical Medicine
World Health Organization
The Zika Virus (ZIKV) is an arbovirus that belongs to the Flavivirus genus and infection follows the bite of an infected Aedes mosquito, and it presents with mild flulike disease symptoms; asymptomatic infection is frequent. A ZIKV infection occurring during the first trimester of pregnancy significantly increases the probability for the fetus to develop microcephaly, a severe and disabling malformation of the brain.
An international team of scientists working with the Bernhard Nocht Institute for Tropical Medicine (Hamburg, Germany) have demonstrate the potential of the bacterially expressed extracellular immunoglobulin-like domain of the human FcμR (HsFcμR-Igl) as a capture molecule for IgM-specific serological testing. As model systems, they chose two viral pathogens, the CCHFV and the ZIKV. In 2015, both were identified as high-risk emerging pathogens by the World Health Organization (WHO, Geneva, Switzerland) likely to cause major epidemics and thus needing urgent investigation and development attention.
His-tagged HsFcμR-Igl was expressed in Escherichia coli and purified by affinity chromatography, oxidative refolding, and size-exclusion chromatography. Specific binding of HsFcμR-Igl to IgM/antigen immune complexes (ICs) was confirmed, and two prototypic enzyme-linked immunosorbent assays (ELISAs) for the detection of anti-CCHFV and anti-ZIKV IgM antibodies were developed. Thereby, patient sera and virus-specific recombinant antigens directly labeled with horseradish peroxidase (HRP) were co-incubated on HsFcμR-Igl-coated ELISA plates. Bound ICs were quantified by measuring turnover of a chromogenic HRP substrate. For all ELISAs, the HRP reaction product was quantified by measuring absorbance (A) at 450 nm and 620 nm on a Spectrostar Nano ELISA reader.
Assay validation was performed using paired serum samples from 15 Kosovar patients with a polymerase chain reaction (PCR)-confirmed CCHFV infection and 28 Brazilian patients with a PCR-confirmed ZIKV infection, along with a panel of a priori CCHFV/ZIKV-IgM-negative serum samples. Both ELISAs were highly reproducible. Sensitivity and specificity were comparable with or even exceeded in-house gold standard testing and commercial kits. Furthermore, latex beads coated with HsFcμR-Igl aggregated upon co-incubation with an IgM-positive serum and HRP-labeled antigen but not with either component alone, revealing a potential for use of HsFcμR-Igl as a capture molecule in aggregation-based rapid tests.
The authors concluded that recombinant HsFcμR-Igl is a versatile capture molecule for IgM/antigen ICs of human and animal origin and can be applied for the development of both plate- and bead-based serological tests. The study was published in the February 2019 issue of the journal Clinical Chemistry.
Related Links:
Bernhard Nocht Institute for Tropical Medicine
World Health Organization
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA